Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Phenyltoloxamine is a first-generation antihistamine of the ethanolamine class with sedative and mild analgesic effects. It acts as an H1 receptor antagonist and is primarily used to treat symptoms of the common cold (such as sneezing, cough, runny nose, watery eyes), allergies (allergic rhinitis and conjunctivitis), and as a short-acting sedative. Due to its central nervous system penetration and tranquilizing properties, it is also used in combination with other agents like acetaminophen or codeine for enhanced analgesia or antitussive effect. Phenyltoloxamine stabilizes mast cells by lowering intracellular calcium levels and reduces inflammatory responses by inhibiting NF-kB signaling pathways[1][2][5][6]. It is most commonly found in over-the-counter combination products for relief of minor aches/pains associated with colds or allergies.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on phenyltoloxamine.